5th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference

7th - 8th March 2024

London, UK

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.
Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.
Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Clinical biomarker identification and qualification 
  • Biomarkers and personalized medicine 
  • Assay development and validation
  • NGS and novel technologies in biomarker discovery
  • Commercialization of biomarkers in therapeutic and CDx applications

  • Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

  • Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

 

SPEAKERS

Debora Souza Da Costa

Debora Souza Da Costa

Biosample Operations Specialist, Roche

Stephanie Traub

Stephanie Traub

Associate Director, Translational Biomarkers & Bioanalysis, UCB

Ron Wolbert

Ron Wolbert

Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB

Patrick Brossard

Patrick Brossard

Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

Smiths Lueong.

Smiths Lueong.

Head, Early Detection and Biomarkers, The Cameroon Consortium for Translational Cancer Research

Christian Garde

Christian Garde

Scientific Director, Bioinformatics, Evaxion Biotech A/S

Nathalie Steinhoff

Nathalie Steinhoff

Scientist, Cancer Immunotherapy, Numab Therapeutics AG

Shidong Jia

Shidong Jia

Founder, CEO, Predicine

ENQUIRE NOW

SPONSORS

Predicine
EpigenDx
Cellecta
M24You
Q2 Solutions
Randox Biosciences

LOCATION

Venue

London, UK

PAST EVENT GALLERY